Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATI-1501 Bioavailability and Taste Test
NCT03337126Phase 1Completed
- Sponsor
- Appili Therapeutics
- Start
- Nov 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of LIKMEZ in anaerobic infection, amebiasis and trichomoniasis (trich) (2 arms), sponsored by Appili Therapeutics. Primary endpoint: Relative bioavailability at 48 hours. Started Nov 2017; status: completed.
02
Drugs
LIKMEZ
03
Conditions
anaerobic infectionamebiasistrichomoniasis (trich)
Beyond the preview
Go deeper on NCT03337126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03337126.